BIOPX vs. FPHAX

Last updated Aug 1, 2026

BIOPX (Baron Opportunity Fund) and FPHAX (Fidelity Select Pharmaceuticals Portfolio) are both mutual funds - BIOPX is a Large Cap Growth Equities fund managed by Baron Capital, while FPHAX is a Health & Biotech Equities fund managed by Fidelity. Over the past 10 years, BIOPX returned 20.20%/yr vs 11.56%/yr for FPHAX. Their 0.60 correlation means they have sometimes moved together and sometimes differently. BIOPX charges 1.31%/yr vs 0.67%/yr for FPHAX.

Performance

BIOPX vs. FPHAX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Baron Opportunity Fund (BIOPX) and Fidelity Select Pharmaceuticals Portfolio (FPHAX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BIOPX achieves a 3.65% return, which is significantly lower than FPHAX's 12.79% return. Over the past 10 years, BIOPX has outperformed FPHAX with an annualized return of 20.20%, while FPHAX has yielded a comparatively lower 11.56% annualized return.

BIOPX

• 1D: 2.06%
• 1M: -8.28%
• 6M: 7.24%
• YTD: 3.65%
• 1Y: 13.16%
• 3Y*: 22.14%
• 5Y*: 8.58%
• 10Y*: 20.20%
• ALL TIME*: 10.31%

FPHAX

• 1D: -1.65%
• 1M: -4.52%
• 6M: 10.36%
• YTD: 12.79%
• 1Y: 48.98%
• 3Y*: 19.23%
• 5Y*: 12.98%
• 10Y*: 11.56%
• ALL TIME*: 9.63%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
BIOPX Baron Opportunity Fund	$0.00	$0.00	$0.00
FPHAX Fidelity Select Pharmaceuticals Portfolio	$0.00	$0.00	$0.00

BIOPX vs. FPHAX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BIOPX Baron Opportunity Fund	3.65%	19.44%	39.87%	49.55%	-42.96%	11.90%	88.78%	40.34%	8.06%	40.58%
FPHAX Fidelity Select Pharmaceuticals Portfolio	12.79%	30.41%	9.39%	12.54%	0.94%	11.79%	11.16%	31.73%	5.41%	10.70%

Correlation

The correlation between BIOPX and FPHAX is 0.22, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.22
Correlation (3Y) Balances recent behavior with more history.	0.33
Correlation (5Y) Shows whether the relationship held over a longer period.	0.42
Correlation (10Y) Provides a long-term view across more market conditions.	0.50
Correlation (All Time) Calculated using the full available price history since Jun 18, 2001	0.60

Over the past year, the correlation between BIOPX and FPHAX has dropped to 0.22 - well below their long-term average of 0.60, suggesting their price drivers have been diverging.

Return for Risk

BIOPX vs. FPHAX — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

BIOPX

BIOPX Risk / Return Rank: 15
BIOPX Sharpe Ratio Rank: 13
BIOPX Sortino Ratio Rank: 15
BIOPX Omega Ratio Rank: 14
BIOPX Calmar Ratio Rank: 16
BIOPX Martin Ratio Rank: 16

FPHAX

FPHAX Risk / Return Rank: 90
FPHAX Sharpe Ratio Rank: 91
FPHAX Sortino Ratio Rank: 89
FPHAX Omega Ratio Rank: 83
FPHAX Calmar Ratio Rank: 96
FPHAX Martin Ratio Rank: 93

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

BIOPX vs. FPHAX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Baron Opportunity Fund (BIOPX) and Fidelity Select Pharmaceuticals Portfolio (FPHAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	BIOPX	FPHAX	Difference
Sharpe ratio: Return per unit of total volatility	0.50	2.32	-1.82
Sortino ratio: Return per unit of downside risk	0.86	3.30	-2.44
Omega ratio: Gain probability vs. loss probability	1.10	1.38	-0.28
Calmar ratio: Return relative to maximum drawdown	0.75	4.53	-3.78
Martin ratio: Return relative to average drawdown	2.11	13.77	-11.66

BIOPX vs. FPHAX - Sharpe Ratio Comparison

The current BIOPX Sharpe Ratio is 0.50, which is lower than the FPHAX Sharpe Ratio of 2.32. The chart below compares the historical Sharpe Ratios of BIOPX and FPHAX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

BIOPX vs. FPHAX - Drawdown Comparison

The maximum BIOPX drawdown since its inception was -67.91%, which is greater than FPHAX's maximum drawdown of -38.26%. Use the drawdown chart below to compare losses from any high point for BIOPX and FPHAX.

Drawdown Indicators

	BIOPX	FPHAX	Difference
Max Drawdown Largest peak-to-trough decline	-67.91%	-38.26%	-29.65%
Max Drawdown (1Y) Largest decline over 1 year	-14.31%	-10.33%	-3.98%
Max Drawdown (3Y) Largest decline over 3 years	-26.34%	-28.82%	+2.48%
Max Drawdown (5Y) Largest decline over 5 years	-51.45%	-28.82%	-22.63%
Max Drawdown (10Y) Largest decline over 10 years	-51.45%	-28.82%	-22.63%
Current Drawdown Current decline from peak	-12.55%	-5.24%	-7.31%
Average Drawdown Average peak-to-trough decline	-16.81%	-9.13%	-7.68%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.09%	3.41%	+1.68%

Volatility

BIOPX vs. FPHAX - Volatility Comparison

Baron Opportunity Fund (BIOPX) and Fidelity Select Pharmaceuticals Portfolio (FPHAX) have volatilities of 6.14% and 6.43%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BIOPX	FPHAX	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.14%	6.43%	-0.29%
Volatility (6M) Calculated over the trailing 6-month period	16.59%	15.25%	+1.34%
Volatility (1Y) Calculated over the trailing 1-year period	21.56%	20.24%	+1.32%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	27.17%	18.35%	+8.82%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.04%	17.93%	+7.11%

BIOPX vs. FPHAX - Expense Ratio Comparison

BIOPX has a 1.31% expense ratio, which is higher than FPHAX's 0.67% expense ratio.

Dividends

BIOPX vs. FPHAX - Dividend Comparison

BIOPX's dividend yield for the trailing twelve months is around 4.09%, less than FPHAX's 4.93% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BIOPX Baron Opportunity Fund	4.09%	4.24%	4.95%	0.00%	0.00%	8.71%	6.96%	7.33%	5.29%	15.58%	13.52%	10.92%
FPHAX Fidelity Select Pharmaceuticals Portfolio	4.93%	5.68%	1.90%	8.08%	5.18%	11.09%	8.85%	8.33%	1.65%	1.62%	1.07%	12.63%

Frequently Asked Questions

Can I hold both BIOPX and FPHAX in my portfolio?

BIOPX and FPHAX have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BIOPX or FPHAX?

FPHAX has higher volatility (6.43%) compared to BIOPX (6.14%). In terms of maximum drawdown, BIOPX dropped -67.91% vs FPHAX's -38.26%.

Which has better risk-adjusted returns?

FPHAX currently has the higher Sharpe Ratio (2.32 vs 0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.